{{NoteTA
|G1=LS
|T=zh:利培酮;zh-hans:利培酮;zh-hant:利培酮;zh-cn:利培酮;zh-tw:理思必妥;zh-hk:維思通;zh-sg:利培酮;zh-mo:利培酮;
|1=zh:利培酮;zh-hans:利培酮;zh-hant:利培酮;zh-cn:利培酮;zh-tw:理思必妥;zh-hk:維思通;zh-sg:利培酮;zh-mo:利培酮;
}}
{{medical}}
{{drugbox
| Watchedfields = changed
| verifiedrevid = 464382756
| IUPAC_name = 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
| image = Risperidone.svg
| width = 250px
| image2 = Risperidone-3D-balls.png
| width2 = 250px
<!--Clinical data-->
| pronounce = 
| tradename = Risperdal及其他<ref name=generics>Drugs.com [https://www.drugs.com/international/risperidone.html International trade names for risperidone] {{webarchive|url=https://web.archive.org/web/20160318043334/http://www.drugs.com/international/risperidone.html |date=2016-03-18 }} Page accessed March 15, 2016</ref>
| Drugs.com = {{drugs.com|monograph|risperidone}}
| MedlinePlus = a694015
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_US = Rx-only
| legal_UK = POM
| routes_of_administration = 口服（錠劑或液狀劑）、[[肌肉注射|肌肉注射]]
<!--Pharmacokinetic data-->
| bioavailability = 70%（口服）<ref name=AHFS2015/>
| metabolism = [[肝臟|肝臟]]（[[CYP2D6|CYP2D6]] mediated to 9-hydroxyrisperidone）<ref name=AHFS2015/>
| elimination_half-life = 20小時（口服），3–6天（肌肉注射）<ref name=AHFS2015/>
| excretion = 尿液（70%）、糞便（14%）<ref name=AHFS2015/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 106266-06-2
| ATC_prefix = N05
| ATC_suffix = AX08
| PubChem = 5073
| IUPHAR_ligand = 96
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00734
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4895
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L6UH7ZF8HC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00426
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8871
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 85
<!--Chemical data-->
| C=23 | H=27 | F=1 | N=4 | O=2
| molecular_weight = 410.485 g/mol
| smiles = Cc1c(c(=O)n2c(n1)CCCC2)CCN3CCC(CC3)c4c5ccc(cc5on4)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RAPZEAPATHNIPO-UHFFFAOYSA-N
}}
<!-- Definition and medical uses -->
'''利培酮'''（{{lang-en|'''Risperidone'''}}），常見商品名'''Risperdal'''，為一種[[抗精神病药|精神科藥物]]<ref name=AHFS2015>{{cite web|title=Risperidone|url=https://www.drugs.com/monograph/risperidone.html|publisher=The American Society of Health-System Pharmacists|accessdate=Dec 1, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151202010615/http://www.drugs.com/monograph/risperidone.html|archivedate=2015-12-02|df=}}</ref>。主要用於治療[[精神分裂症|思覺失調症]]、[[雙相情緒障礙症|雙相情緒障礙症]]，以及[[自閉症|自閉症]]症狀者的易怒情形<ref name=AHFS2015/>。本品可口服或[[肌肉注射|肌肉注射]]給藥<ref name=AHFS2015/>。注射劑型的藥效可維持長達兩周<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|pages=434–435}}</ref>。

<!-- Side effects -->
常見副作用包含[[錐體外症候群|動作障礙]]、{{tsl|en|sedation|鎮靜|嗜睡}}、視力問題、便秘，以及體重增加等等<ref name=AHFS2015/><ref>{{cite journal |vauthors=Hasnain M, Vieweg WV, Hollett B | title = Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians | journal = Postgraduate Medicine | volume = 124 | issue = 4 | pages = 154–67 | date = July 2012 | pmid = 22913904 | doi = 10.3810/pgm.2012.07.2577 }}</ref>。嚴重副作用包含[[遲發性運動不能|遲發性運動不能]]及{{tsl|en|neuroleptic malignant syndrome|抗精神藥物惡性症候群}}等永久性的動作障礙。本品亦可能提高[[自殺|自殺]]及[[高血糖|高血糖]]的風險<ref name=AHFS2015/><ref name=Ric2015/>。在因[[失智症|失智症]]導致[[思覺失調|思覺失調]]的年長者身上用藥，可能會提升死亡風險<ref name=AHFS2015/>。[[妊娠|妊娠]]期間用藥的安全性迄今未明<ref name=AHFS2015/>。本品屬於{{tsl|en|atypical psychotic|非典型抗精神病药}}<ref name=AHFS2015/>。其作用機轉目前未明，可能與其 {{tsl|en|dopamine antagonist|

多巴胺拮抗劑}}的活性<ref name=AHFS2015/>。

<!-- History, society, and culture -->
有關利培酮的研究始於1980年代，並於1993年在美國核准上市<ref name=AHFS2015/><ref>{{cite book|last1=Nemeroff|first1=edited by Alan F. Schatzberg, Charles B.|title=The American Psychiatric Publishing textbook of psychopharmacology|date=2009|publisher=American Psychiatric Pub.|location=Washington, D.C.|isbn=9781585623099|page=627|edition=4th|url=https://books.google.com/books?id=Xx7iNGdV25IC&pg=PA627|deadurl=no|archiveurl=https://web.archive.org/web/20160305092127/https://books.google.com/books?id=Xx7iNGdV25IC&pg=PA627|archivedate=2016-03-05|df=}}</ref>。本品列名於[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]，為基礎公衛體系必備藥物之一<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref>。本品屬於[[通用名药物|通用名药物]]<ref name=Ric2015/>。在2014年，每日劑量[[发展中国家|发展中国家]]的批發價介於0.01到0.60美金之間<ref>{{cite web|title=Risperidone|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=1465&searchYear=2014|website=International Drug Price Indicator Guide|accessdate=2 December 2015|archive-date=2018-01-22|archive-url=https://web.archive.org/web/20180122072914/http://mshpriceguide.org/en/single-drug-information/?DMFId=1465&searchYear=2014|dead-url=no}}</ref>。2015年，每月正常劑量約介於100到200美金之間<ref name=Ric2015/>。

==药理作用==
利培酮是一种[[选择性单胺能拮抗剂|选择性单胺能拮抗剂]]，它与[[5-羟色胺|5-羟色胺]]能的5-HT<sub>2</sub>受体和多巴胺能的D<sub>2</sub>受体有很高的亲和力，也能与α<sub>1</sub>-[[肾上腺素能受体|肾上腺素能受体]]结合，与H<sub>1</sub>-组胺受体和α<sub>2</sub>肾上腺素能受体的亲和力较低，但不能与[[胆碱能受体|胆碱能受体]]结合。利培酮是强有力的D<sub>2</sub>拮抗剂，这是它抑制精神分裂症[[阳性症状|阳性症状]]的原因，但它引起的运动功能抑制及强直性昏厥都要比经典抗精神分裂症药要少，对中枢系统的5-羟色胺和多巴胺拮抗作用的平衡可以减轻发生锥体外系反应，并将其治疗作用扩展到精神分裂症的[[阴性症状|阴性症状]]和[[情感症状|情感症状]]。
[[File:Risperidone icon.svg|thumb|none|利培酮抑制D-氨基酸氧化酶催化D-氨基酸的分解（例如D-丙氨酸和D-絲氨酸 - 神經遞質）。
]]

==适用症==
利培酮是一种非经典抗精神病药，适用于：
*治疗成人和13-17岁青少年的精神分裂症
*单独，或与[[锂|锂]]或[[丙戊酸盐|丙戊酸盐]]组合，短期治疗成人[[急性躁狂|急性躁狂]]或[[I型双极症|I型双极症]]关联的混合发作，且对10-17岁儿童和青少年单独使用<ref>[http://www.fda.gov/cder/foi/label/2007/020272s46s47,20588s36s37,21444s20s21lbl.pdf RISPERDAL  Label] {{Wayback|url=http://www.fda.gov/cder/foi/label/2007/020272s46s47,20588s36s37,21444s20s21lbl.pdf |date=20081005082658 }}，FDA/Center for Drug Evaluation and Research</ref>

==不良反应==
常見的副作用包含發生[[錐體外症候群|錐體外症候群]]、嗜睡、便秘、反眼以及體重增加等情形<ref name=AHFS2015/><ref>{{cite journal | author = Hasnain M, Vieweg WV, Hollett B | title = Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians | journal = Postgraduate Medicine | volume = 124 | issue = 4 | pages = 154–67 | date = July 2012 | pmid = 22913904 | doi = 10.3810/pgm.2012.07.2577 }}</ref>。嚴重的副作用包含永久性的行為疾患[[遲發性運動障礙|遲發性運動障礙]]像是[[抗精神藥物惡性症候群|抗精神藥物惡性症候群]]，增加[[自殺|自殺]]的風險、以及[[高血糖|高血糖]]等<ref name=AHFS2015/><ref name=Ric2015/>。患有[[精神病|精神病]]的中高齡患者得到[[失智症|失智症]]可能因此病而提高了死亡風險。目前對[[懷孕|懷孕]]患者的影響尚不明朗。理思必妥是一種[[非典型抗精神病藥|非典型抗精神病藥]]，其作用方式尚未完全釐清，但據稱是一種多巴胺拮抗劑<ref name=AHFS2015/>。

==歷史、社會與文化==
對理思必妥的研究始於1980年代後期，美國於1993年正式批准此藥上市，<ref>{{cite book|last1=Nemeroff|first1=edited by Alan F. Schatzberg, Charles B.|title=The American Psychiatric Publishing textbook of psychopharmacology|date=2009|publisher=American Psychiatric Pub.|location=Washington, D.C.|isbn=9781585623099|page=627|edition=4th ed.|url=https://books.google.ca/books?id=Xx7iNGdV25IC&pg=PA627|access-date=2017-05-15|archive-date=2018-09-16|archive-url=https://web.archive.org/web/20180916040424/https://books.google.ca/books?id=Xx7iNGdV25IC&pg=PA627|dead-url=no}}</ref><ref name="AHFS2015" />在最基本的健康照護系統中最必要的藥物清單[[世界衛生組織基本藥物標准清單|世界衛生組織基本藥物標准清單]]登錄有案，<ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013|archive-date=2014-04-23|archive-url=https://web.archive.org/web/20140423005004/http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|dead-url=no}}</ref> 理思必妥亦有學名藥物，<ref name="Ric2015" />2014年，批發價約在0.01到0.60美元之間<ref>{{cite web|title=Risperidone|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RIS1T&s_year=2014&year=2014&str=1%20mg&desc=Risperidone&pack=new&frm=TAB-CAP&rte=PO&class_code2=24%2E1%2E&supplement=&class_name=%2824%2E1%2E%29Medicines%20used%20in%20psychotic%20disorders%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=2 December 2015}}{{Dead link|date=2018年6月 |bot=InternetArchiveBot |fix-attempted=no }}</ref>。在美國每劑藥物售價是3.3美金到10美金左右<ref name="AHFS2015" />。

==参考文献==
{{reflist|2}}

==外部連結==
{{commons category|Risperidone}}
* [https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=475100 PubChem Substance Summary: Risperidone] {{Wayback|url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=475100 |date=20140808125442 }}—National Center for Biotechnology Information.
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Risperidone Drug Information Portal—Risperidone] {{Wayback|url=http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Risperidone |date=20100612075143 }}—[[United_States_National_Library_of_Medicine|U.S. National Library of Medicine]]
* [http://www.hma.eu/fileadmin/dateien/pipar/dk1316risperidonnycomed/parmod5_dk1316risperidonnycomed.pdf Description of risperidone "Nycomed" medicine, Danish link in English language] {{Wayback|url=http://www.hma.eu/fileadmin/dateien/pipar/dk1316risperidonnycomed/parmod5_dk1316risperidonnycomed.pdf |date=20180916040355 }}

{{Mood stabilizers}}
{{Hypnotics and sedatives}}
{{抗精神病药物}}
{{Adrenergic receptor modulators}}
{{Histaminergics}}
{{Serotonergics}}
{{portal bar|藥理學|醫學|精神病學}}

{{DEFAULTSORT:Risperidone}}
[[Category:非典型抗精神病药|Category:非典型抗精神病药]]
[[Category:自閉症|Category:自閉症]]
[[Category:比利時發明|Category:比利時發明]]
[[Category:氟代芳烴|Category:氟代芳烴]]
[[Category:H1受体拮抗剂|Category:H1受体拮抗剂]]
[[Category:强生品牌|Category:强生品牌]]
[[Category:楊森製藥|Category:楊森製藥]]
[[Category:内酰胺|Category:内酰胺]]
[[Category:情感障碍|Category:情感障碍]]
[[Category:哌啶|Category:哌啶]]
[[Category:嘧啶酮|Category:嘧啶酮]]
[[Category:血清素拮抗剂|Category:血清素拮抗剂]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]